Comparison 11. Efficacy at six months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ACR20	2	346	Risk Ratio (M‐H, Random, 95% CI)	1.19 [0.85, 1.66]
1.1 Etanercept 25 mg SC twice weekly	2	346	Risk Ratio (M‐H, Random, 95% CI)	1.19 [0.85, 1.66]
2 ACR50	2	346	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.99, 1.49]
2.1 Etanercept 25 mg SC twice weekly	2	346	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.99, 1.49]
3 ACR70	2	346	Risk Ratio (M‐H, Fixed, 95% CI)	1.30 [0.92, 1.85]
3.1 Etanercept 25 mg SC twice weekly	2	346	Risk Ratio (M‐H, Fixed, 95% CI)	1.30 [0.92, 1.85]
4 DAS < 3.2	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.56 [1.05, 2.33]
4.1 Etanercept 25 mg SC twice weekly	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.56 [1.05, 2.33]
5 Remission (DAS < 2.6)	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	2.70 [1.22, 5.98]
5.1 Etanercept 25 mg SC twice weekly	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	2.70 [1.22, 5.98]
6 EULAR ‐ good response	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.56 [1.05, 2.33]
6.1 Etanercept 25 mg SC twice weekly	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.56 [1.05, 2.33]
7 EULAR ‐ moderate response	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.78, 1.73]
7.1 Etanercept 25 mg SC twice weekly	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.78, 1.73]
8 EULAR ‐ no response	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.04, 0.46]
8.1 Etanercept 25 mg SC twice weekly	1	142	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.04, 0.46]
9 DAS	1	204	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.32, 0.32]
9.1 ET 25 mg SC twice weekly	1	204	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.32, 0.32]